Franciscan Health Cancer Center Indianapolis
Indianapolis, IN
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 2
Not yet accepting
MagnetisMM-15
Elranatamab Post Trial Access: An Open-Label, Single-Arm Study For Participants with Multiple Myeloma Continuing From Pfizer-Sponsored Elranatamab Clinical Studies
- Bispecific Antibody
- BCMA
- CD3
- Phase 4
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials1 hidden based on your filters. Show All